Phase I/II study of VEGFR1/2-derived peptide vaccination in combination with a 5-fluorouracil derivative (TS-1) for metastatic colorectal cancer with KRAS genetic mutation as a third-line therapy

Interventions: KRAS genetic sequence, peptide vaccination, TS1
Primary outcome(s): First step (clinical phase I) Primary Endpoint: RD Second step (clinical phase II) Primary Endpoint: DCR
Study Design: Single arm Non-randomized